

Application No.: 10/072,602
Supplemental Amendment Dated 20 July 2004
Further reply to Office Action of 9 June 2004

REMARKS

Claims 10 and 11 have been amended to specify "isolated" rather than "substantially pure." Claims 15 and 18 have been amended to delete the specific peptides and propeptides disclosed in U.S. application Serial No. 09/580,201.

New claims 20-22 have been added to claim the subject matter directed to the Mar-type conopeptides set forth in Table 5 of the specification in which Pro residues are substituted by hydroxy-Pro residues as noted in Table 5. New claim 23 have been added to claim the generic peptides of the peptides set forth in Table 5, for which support can be found in Table 1. New claim 24 has been added to claim the generic peptide for the elected peptide (i.e., SEQ ID NO:534), for which support can be found in Table 1.

It is submitted that these amendment do not constitute new matter and their entry is requested.


The elected peptide (SEQ ID NO:534) reads on new claims 23 and 24, as well as claims 1, 2 and 15-17. The corresponding propeptide (SEQ ID NO:352) reads on claims 6, 18 and 19.

As set forth in the Amendment and Response to Restriction Requirement filed on 9 July 2004, Applicants submit that all of the Mar-type peptides should be examined together, and accordingly, the election of the peptide of SEQ ID NO:534 is made with traverse.

Respectfully submitted,

ROTHWELL, FIGG, ERNST & MANBECK, p.c.

By _____


Jeffrey L. Ihnen
Registration No. 28,957
Attorney for Applicant
1425 K Street, N.W., Suite 800
Washington, D.C. 20005
phone: 202-783-6040
fax: 202-783-6031